Company / Cash & Equivalents
IONIS PHARMACEUTICALS INC Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$372.3M
FY2025
5-year range
$242.1M / $869.2M
FY2021-FY2025
Trend
+53.8%
vs FY2024
Sector context
#52 of 207
Health Care
What the data says
IONIS PHARMACEUTICALS INC's cash & equivalents of $372M is higher than 75% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $85M in FY2016 to $869M in FY2021.
Based on SEC 10-K filings.
$372M in FY2025 with a 5-year CAGR of -1.3%. Top quartile in the Health Care sector.
Declined from $399M to $372M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +10.4%
- 5-Year CAGR
- -1.3%
- 10-Year CAGR
- -
Sector benchmark
-44.4% below sector average
Key checks
Key Insights
- 5-year CAGR of -1.3%, indicating a declining trend.
- In FY2025, cash & equivalents increased 53.8% year-over-year.
- Ranks #52 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $372.3M | +53.8% |
| FY2024 | $242.1M | -39.4% |
| FY2023 | $399.3M | +44.4% |
| FY2022 | $276.5M | -68.2% |
| FY2021 | $869.2M | +118.6% |
| FY2020 | $397.7M | -41.8% |
| FY2019 | $683.3M | +145.1% |
| FY2018 | $278.8M | +115.1% |
| FY2017 | $129.6M | +53.1% |
| FY2016 | $84.7M | -34.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026